For patients with intermediate- or low-risk localized prostate cancer, intensity-modulated radiation therapy (IMRT) and proton beam therapy are both safe and effective options, according to results of ...

Patient-reported quality of life (QoL) was similar between proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) among men with localized prostate cancer, the randomized PARTIQoL ...

With smaller radiation beams, intensity-modulated radiation therapy “takes precision to the next level” for patients with prostate, an expert told CURE®. Intensity-modulated radiation therapy (IMRT) — ...

Back in the late 1980s, researchers at Varian Medical Systems Inc. had a vision for how to make radiation therapy for treating cancer more powerful, more efficient and much safer. They just didnt have ...

A large trial of people with earlier stages of prostate cancer compared two types of external radiation treatments head-to-head—proton beam therapy and intensity-modulated radiation therapy, or ...

WASHINGTON, September 30, 2024 — People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated ...

People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy - proton beam therapy or intensity modulated radiation therapy (IMRT) - ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

A new study compares outcomes among younger men with prostate cancer who are treated with intensity-modulated radiotherapy (IMRT), which is the most commonly used form of radiotherapy (RT) in the ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...